A Study of NX-1607 in Adults With Advanced Malignancies
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Ovarian Cancer, Epithelial|Gastric Cancer|GastroEsophageal Junction (GEJ) Cancer|Head and Neck Squamous Cell Carcinoma|Metastatic or Unresectable Melanoma|Non-small Cell Lung Cancer (NSCLC)|Metastatic Castration-resistant Prostate Cancer (mCRPC)|Malignant Pleural Mesothelioma (MPM)|Triple Negative Breast Cancer (TNBC)|Metastatic Urothelial Carcinoma|Cervical Cancer|Diffuse Large B Cell Lymphoma (DLBCL)|Richter Transformation|Microsatellite Stable Colorectal Carcinoma
Interventions: DRUG: NX-1607|DRUG: Paclitaxel
Sponsor: Nurix Therapeutics, Inc.